INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,046,019 | +288.1% | 6,130,000 | +240.6% | 0.27% | +423.1% |
Q1 2020 | $1,558,000 | -78.9% | 1,800,000 | -67.6% | 0.05% | -58.4% |
Q4 2019 | $7,399,000 | -16.9% | 5,550,000 | -43.7% | 0.12% | -3.8% |
Q3 2019 | $8,902,000 | +79.0% | 9,850,000 | +97.0% | 0.13% | +128.1% |
Q2 2019 | $4,973,000 | – | 5,000,000 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |